LifeStance Raises FY23 Revenue Of $1.01B-$1.04B Versus Prior Guidance Of $990M-$1.02B And Consensus Of $1.01B; Sees Center Margin Of $280M-$300M Versus Earlier Guidance Of $274M-$290M
Portfolio Pulse from Benzinga Newsdesk
LifeStance Health Group, Inc. (LFST) has raised its FY23 revenue guidance to $1.01B-$1.04B, up from the previous guidance of $990M-$1.02B. The company also increased its center margin guidance to $280M-$300M, up from the earlier guidance of $274M-$290M.
August 09, 2023 | 10:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
LifeStance's raised FY23 revenue and center margin guidance may positively impact its stock price in the short term.
LifeStance's raised FY23 revenue and center margin guidance indicates better-than-expected performance, which is likely to be viewed positively by investors and could lead to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100